- Home
- CCSI vs MYGN Comparison
CCSI vs MYGN Comparison
Compare CCSI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCSI
- MYGN
- Stock Information
- Founded
- CCSI 2021
- MYGN 1991
- Country
- CCSI United States
- MYGN United States
- Employees
- CCSI N/A
- MYGN N/A
- Industry
- CCSI Retail: Computer Software & Peripheral Equipment
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CCSI Technology
- MYGN Health Care
- Exchange
- CCSI Nasdaq
- MYGN Nasdaq
- Market Cap
- CCSI 450.6M
- MYGN 423.1M
- IPO Year
- CCSI N/A
- MYGN 1995
- Fundamental
- Price
- CCSI $23.84
- MYGN $6.32
- Analyst Decision
- CCSI Hold
- MYGN Hold
- Analyst Count
- CCSI 5
- MYGN 15
- Target Price
- CCSI $27.20
- MYGN $15.14
- AVG Volume (30 Days)
- CCSI 156.2K
- MYGN 2.3M
- Earning Date
- CCSI 08-07-2025
- MYGN 08-05-2025
- Dividend Yield
- CCSI N/A
- MYGN N/A
- EPS Growth
- CCSI N/A
- MYGN N/A
- EPS
- CCSI 4.15
- MYGN N/A
- Revenue
- CCSI $349,595,000.00
- MYGN $832,900,000.00
- Revenue This Year
- CCSI $1.18
- MYGN N/A
- Revenue Next Year
- CCSI $0.56
- MYGN $6.64
- P/E Ratio
- CCSI $5.74
- MYGN N/A
- Revenue Growth
- CCSI N/A
- MYGN 3.83
- 52 Week Low
- CCSI $17.84
- MYGN $3.76
- 52 Week High
- CCSI $32.10
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CCSI 65.78
- MYGN 70.39
- Support Level
- CCSI $19.42
- MYGN $3.76
- Resistance Level
- CCSI $21.79
- MYGN $4.09
- Average True Range (ATR)
- CCSI 0.83
- MYGN 0.30
- MACD
- CCSI 0.22
- MYGN 0.23
- Stochastic Oscillator
- CCSI 69.66
- MYGN 96.97
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.